KNTE — Kinnate Biopharma Share Price
0.000.00%
Last trade - 00:00- $125.62m
- -$28.41m
- 28
- 38
- 57
- 35
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.79 | ||
| Price to Tang. Book | 0.79 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -74.98% | ||
| Return on Equity | -58.86% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Kinnate Biopharma Inc. is a clinical-stage precision oncology company. It is focused on the discovery, design and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. Its lead product candidate is exarafenib (KIN-2787), which is a Rapidly Accelerated Fibrosarcoma (RAF) inhibitor in development for the treatment of patients with lung cancer, melanoma and other solid tumors. Its second product candidate is KIN-3248, a Fibroblast Growth Factor Receptors (FGFR) inhibitor, designed for the treatment of patients with intrahepatic cholangiocarcinoma (ICC). KIN-3248 is designed to address clinically observed kinase domain mutations in FGFR2 and FGFR3. It is also advancing other small molecule research programs, including a Cyclin-Dependent Kinase 12 (CDK12) inhibitor in its KIN004 program for the treatment of ovarian carcinoma (OC), triple-negative breast cancer (TNBC) and metastatic castration-resistant prostate cancer (mCRPC).
Directors
- Dean Mitchell NEC (65)
- Nima Farzan PRE (45)
- Mark Meltz COO (47)
- Richard Williams OTH (52)
- Helen Sabzevari DRC
- Laurie Alsup IND (67)
- Melissa Epperly IND (43)
- Keith Flaherty IND (50)
- Carl Gordon IND (56)
- Michael Rome IND (36)
- Jim Tananbaum IND (57)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- January 1st, 2018
- Public Since
- December 3rd, 2020
- No. of Shareholders
- 11
- No. of Employees
- 27
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 47,225,312
- Address
- 11975 El Camino Real, Ste 101, Suite 101, SAN DIEGO, 92130
- Web
- https://www.kinnate.com/
- Phone
- +1 8582994699
- Auditors
- KPMG LLP
Upcoming Events for KNTE
Q2 2024 Kinnate Biopharma Inc Earnings Release
Similar to KNTE
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Kinnate Biopharma share price?
As of Today at 19:12 UTC, shares in Kinnate Biopharma are trading at $2.66. This share price information is delayed by 15 minutes.
How has the Kinnate Biopharma share price performed this year?
Shares in Kinnate Biopharma last closed at $2.66 and the price had moved by -56.68% over the past 365 days. In terms of relative price strength the Kinnate Biopharma share price has underperformed the S&P500 Index by -66.12% over the past year.
What are the analyst and broker recommendations for Kinnate Biopharma?
The overall consensus recommendation for Kinnate Biopharma is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Kinnate Biopharma dividend yield?
Kinnate Biopharma does not currently pay a dividend.
Does Kinnate Biopharma pay a dividend?
Kinnate Biopharma does not currently pay a dividend.
When does Kinnate Biopharma next pay dividends?
Kinnate Biopharma does not currently pay a dividend.
How do I buy Kinnate Biopharma shares?
To buy shares in Kinnate Biopharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Kinnate Biopharma?
As of the previous close price of $2.66, shares in Kinnate Biopharma had a market capitalisation of $125.62m.
Where are Kinnate Biopharma shares listed?
Here are the trading details for Kinnate Biopharma:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: KNTE
What kind of share is Kinnate Biopharma?
Based on an overall assessment of its quality, value and momentum Kinnate Biopharma is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Kinnate Biopharma share price forecast for 2024?
The analyst consensus target price for shares in Kinnate Biopharma is $2.36. That is 11.28% below the last closing price of $2.66.
Analysts covering Kinnate Biopharma currently have a consensus Earnings Per Share (EPS) forecast of -$1.32 for the next financial year.
What is the trend in the Kinnate Biopharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Kinnate Biopharma. Over the past six months, its share price has outperformed the S&P500 Index by +55.07%.
As of the last closing price of $2.66, shares in Kinnate Biopharma were trading +16.67% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Kinnate Biopharma PE Ratio?
The Kinnate Biopharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.66.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Kinnate Biopharma?
Kinnate Biopharma's management team is headed by:
- Dean Mitchell - NEC
- Nima Farzan - PRE
- Mark Meltz - COO
- Richard Williams - OTH
- Helen Sabzevari - DRC
- Laurie Alsup - IND
- Melissa Epperly - IND
- Keith Flaherty - IND
- Carl Gordon - IND
- Michael Rome - IND
- Jim Tananbaum - IND